title: A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
abstract: BACKGROUND
  Plasmablastic lymphoma (PBL) is an uncommon variant of diffuse large B-cell lymphoma that is characterized by its plasmacytoid features, aggressive tendencies, and frequent association with human immunodeficiency virus (HIV) infection or other immunocompromised states. Multi-agent, intensive chemotherapy regimens are recommended as first-line treatment by the National Comprehensive Cancer Network. However, the toxicity of these regimens is high and prognosis remains poor.
  
  
  METHODS
  We report a patient with HIV-negative PBL who achieved complete response and durable remission using a lenalidomide-based chemotherapy regimen as first-line therapy.
  
  
  CONCLUSIONS
  Cyclophosphamide, lenalidomide, dexamethasone (CRD) may provide an alternative initial therapeutic option for patients with PBL who cannot tolerate the intensive chemotherapy regimens currently recommended.
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Schmit
authors.forename: Jess
authors.initials: J
authors.lastname: DeLaune
authors.forename: Maxim
authors.initials: M
authors.lastname: Norkin
authors.forename: Alan
authors.initials: A
authors.lastname: Grosbach
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000072226:Computed Tomography Angiography; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis; D018023:HIV Seronegativity; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D000069293:Plasmablastic Lymphoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012074:Remission Induction; D012811:Sigmoid Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D003520:Cyclophosphamide; D000077269:Lenalidomide